Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 1, 2009, Pages 153-159

  Otaegui, Dorleta ^a   Rodríguez Gascón, Alicia ^a   Zubia, Aizpea ^a,b   Cossío, Fernando P ^a   Pedraz, José Luis ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Ikerchem SL   (Spain)

Author keywords

HDAC inhibitors; Kendine 91; Mice; Oral bioavailability; Pharmacokinetics

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; EX 2; HISTONE DEACETYLASE INHIBITOR; KENDINE 91; PANOBINOSTAT; SB 639; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER BLOOD FLOW; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HALF-LIFE; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRROLES; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 67349277416     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0857-9     Document Type: Article

References (19)

1. RP Warrell LZ He VM Richon 1998 Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J Natl Cancer Inst 90 1621 1625 (Pubitemid 28523436)
2. L Pasqualucci A Migliazza K Basso 2003 Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B cell lymphoma Blood 101 2914 2923 (Pubitemid 36857975)
3. PA Marks VM Richon T Miller 2004 Histone deacetylase inhibitors Adv Cancer Res 91 137 168 (Pubitemid 39140958)
4. PA Marks VM Richon RA Rifkind 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J Natl Cancer Inst 92 1210 1216 (Pubitemid 30627729)
5. P Marks RA Rifkind VM Richon 2001 Histone deacetylases and cancer: causes and therapies Nat Rev Cancer 1 194 202 (Pubitemid 33741894)
6. VM Richon S Emiliani E Verdin 1998 A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Proc Natl Acad Sci USA 95 3003 3007 (Pubitemid 28135844)
7. LM Butler DB Agus HI Scher 2000 Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Res 60 5165 5170
8. PR Venkatesh E Goh P Zeng 2007 In Vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species Biol Pharm Bull 30 5 1021 1024 (Pubitemid 46708656)
9. Cossío FP, Esteller M, Zubia A, Otaegui D (2007) Novel pyrrole derivatives with histone deacetylase inhibitor activity. WO/2007/074176
10. D Otaegui A Rodríguez-Gascón A Zubia 2008 Development and validation of a liquid chromatography-tandem mass spectrometry for the determination of Kendine91, a novel histone deacetylase inhibitor, in mice plasma and tissues: application to a pharmacokinetic study J Chromatogr B 870 1 109 116 (Pubitemid 50014855)
11. P Yeo L Xin E Goh 2007 Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)- hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies Biomed Chromatogr 21 184 189 (Pubitemid 46263995)
12. WK Kelly VM Richon O O'Connor 2003 Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 1 9 3578 3588 (Pubitemid 37169221)
13. WK Kelly OA O'Connor LM Krug 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 17 3923 3931 (Pubitemid 46218695)
14. L Jia PE Noker L Coward 2006 Interspecies pharmacokinetics and in vitro metabolism of SQ109 Br J Pharmacol 147 5 476 485 (Pubitemid 43355045)
15. JL Merdink RD Stenner DK Stevens 1999 Effect of enterohepatic circulation on the disposition of chloral hydrate and its metabolites in F-344 rats J Toxicol Environ Health A 56 357 368 (Pubitemid 29341303)
16. JL Merdink LM Robison DK Stevens 2008 Kinetics of chloral hydrate and its metabolites in male human volunteers Toxicology 245 1/2 130 140
17. B Davies T Morris 1993 Physiological parameters in laboratory animals and humans Pharm Res 10 7 1093 1095 (Pubitemid 23211439)
18. Y Zhang Y Hua DM Benbrook 2006 High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2 Cancer Chemother Pharmacol 58 5 561 569 (Pubitemid 44167380)
19. JW Mouton U Theuretzbacher WA Craig 2008 Tissue concentrations: do we ever learn? J Antimicrob Chemother 61 2 235 237